Edward Graham is Senior Analyst/Consultant, previously responsible for all healthcare positions in the UBS U.S. Small Cap Funds. He has 13 years of buy-side experience in Healthcare with a specialty in Medical Devices and Biotech investing. While at UBS, he developed a unique biotech investment strategy that captured alpha and reduced event risk. The strategy involved buying a basket of small cap biotech stocks with strong cash positions, diverse pipelines, and solid management teams. Edward is dedicated to growth investing with expertise as a partner for an independent asset management boutique and as an investment team member for a multinational financial institution. Unique accomplishments include driving the growth of a start-up investment firm from $250M to $2B in AUM.
Todd Walker is the Executive Director and Chief Strategist at HedgeTracker, where he is responsible for overseeing research, analytics and business development. He has particular expertise in investments that are popular among elite hedge fund managers, shareholder activists and green/sustainability-oriented investors. Prior to joining HedgeTracker in 2003, Mr. Walker headed up a hedge fund research team at a Fortune 1000 financial firm.
Tom Galvin has 26 years of Wall Street experience including 10 years as a highly rated sell side tech analyst at Lehman Brothers, Smith Barney; 15 years as a buyside analyst, director of research, portfolio manager and Chief Investment Office at Forstmann Leff and UBS; Managing Partner at Galvin Asset Management - long/short global equity and all cap growth portfolios.